

Ref: MHL/Sec&Legal/2024-25/79

January 06, 2025

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Ltd.
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Code of Fair Disclosure of Unpublished Price Sensitive Information & Policy for Legitimate Purpose in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has provided a business update for the quarter ended December 31, 2024.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended December 31, 2024. A detailed information update will follow once the Board of Directors approve the financial results for Q3FY25.

In Q3FY25, the Company recorded double-digit revenue growth during a period that is generally a seasonally lean period for diagnostic companies, particularly those operating in the West and South regions. Additionally, the Company achieved a modest year-on-year increase in margins despite seasonally lower revenue growth and constrained operating leverage.

The Company reported mid-teens revenue growth in its B2C segment and low double-digit growth in its B2B segment. However, overall revenue growth was affected by a decline in the institutional business, which is not a primary focus for the Company. Truhealth wellness and bundling segment has performed exceptionally well, emerging as the fastest-growing category with an impressive growth rate of approximately 25% for Q3FY25.

The Company is optimistic about future revenue growth and margin expansion and is open to inorganic opportunities to drive further growth.

Please find below the key highlights of Q3FY25:

1. Revenues grew by approx. **11%** on a Y-o-Y basis. Revenue growth was driven by patient volume growth, test volume growth and change in product mix coupled with realization benefits.
2. B2C revenues grew at approx. **15%** on a Y-o-Y basis on account of industry-leading testing capabilities and strong brand appeal among end consumers. Company is considering a price increase in the B2C in some cities in India effective Q4FY25.
3. Company is debt free & having cash reserves of approximately **INR 200 crores** as on December 31, 2024.

The quarterly business update is on a consolidated basis. The financial results of Q3FY25 are subject to review by Auditors.

Thanking you,
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni
Head – Legal & Secretarial

